Patents
Sitemap › C07 - Organic chemistry › C07D - Heterocyclic compounds › C07D 487 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups
Patents for C07D 487 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups (57,272)
11/2005
11/09/2005CN1694706A Novel imidazopyrazines as cyclin dependent kinase inhibitors
11/09/2005CN1694705A Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
11/09/2005CN1694698A Pyrazolopyridines and methods of making and using the same
11/08/2005WO2005073234A2 Imidazo[1,2-c]pyrimidinylacetic acid derivatives
11/08/2005US6963080 Thin film transistors using solution processed pentacene precursor as organic semiconductor
11/08/2005US6962995 Phenanthroline derivatives
11/08/2005US6962993 Useful as inhibitors of protein kinases, such as the enzyme Janus Kinase 3
11/08/2005US6962920 6-aminofuro(2,3-d)pyrimidines and 6-aminopyrrolo(2,3-d) pyrimidines useful in treating cancer, and secondary infections caused by Pneumocystis carinii and Toxoplasmosis gondii
11/08/2005US6962919 Gonadotropin-releasing hormone antagonizing activity; useful as prophylactic or therapeutic agent for sex hormone-dependent diseases
11/08/2005US6962918 Hexahydropyrazino[1'2';1,6]pyrido[3,4-b]indole-1,4-diones for the treatment of cardiovascular disorders and erectile dysfunction
11/08/2005US6962915 Antiinflammatory agents
11/08/2005US6962912 Substituted pyrazolo[4,3-e]diazepines, pharmaceutical compositions containing them, use as medicinal products and processes for preparing them
11/08/2005US6962911 Treatment of impotence, sexual dysfunction in female, stable, unstable and variant angina, hypertension, pulmonary hypertension, congestive heart failure, atherosclerosis
11/08/2005CA2247020C Possibly substituted 8-cyano-1-cyclopropyl-7-(2,8-diazabicyclo-[4.3.0]-nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolin carboxylic acids and their derivatives
11/03/2005WO2005103056A2 Preparation of metal mesoporphyrin halide compounds
11/03/2005WO2005103055A1 PYRAZOLO-[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PYRIMIDINE ADENOSINE A2A RECEPTOR ANTAGONISTS
11/03/2005WO2005103054A2 Bridged piperazine and piperidine derivatives as ccri antagonists
11/03/2005WO2005103053A1 Processes of preparing glycolurils and cucurbiturils using microwave
11/03/2005WO2005103052A1 Pyrazolo [1,5-a] pyrimidin-7-one compounds and uses thereof
11/03/2005WO2005103039A1 2- (3-aminopyrrolidin-1-yl) pyridines as melanin-concentrating hormone receptor an tagonists
11/03/2005WO2005103012A1 Hydrazino-substituted heterocyclic nitrile compounds and use thereof
11/03/2005WO2005102323A2 Process of preparing esters and ethers of probucol and derivatives thereof
11/03/2005WO2005037214A3 Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication
11/03/2005WO2004096131A3 Inhibitors of akt activity
11/03/2005WO2004072243A3 Macrocyclic hepatitis c serine protease inhibitors
11/03/2005US20050245742 Process for the preparation of zaleplon
11/03/2005US20050245592 2-Iminopyrrolidine derivatives
11/03/2005US20050245565 Diamine derivatives
11/03/2005US20050245554 Substituted pyrimidines
11/03/2005US20050245544 Novel pharmaceuticals
11/03/2005US20050245538 Dipeptidyl peptidase inhibitor; antidiabetic agents; obesity; viricides; anticancer agents; oral diseases; autoimmune disease
11/03/2005US20050245528 Reverse-turn mimetics and compositions and methods related thereto
11/03/2005US20050245517 2-pyridinyl[7-(substituted-pyridin-4-yl) pyrazolo[1,5-a]pyrimidin-3-yl]methanones
11/03/2005US20050245513 Hetero-bridge substituted 8-arylquinoline pde4 inhibitors
11/03/2005US20050245512 Method and composition for rejuvinating cells, tissues organs, hair and nails
11/03/2005US20050245505 Novel heterocyclic compounds, method for preparing same and use thereof as medicines, in particular as antibacterial agents
11/03/2005US20050241080 High fixing yields and high fiber-dye binding stability; it should also be possible for dye that is not fixed to be washed off easily; colorfastness; dyeing or printing of hydroxyl-group-containing or nitrogen-containing, especially cotton-containing materials; ink jet printing inks
11/03/2005DE102004018796A1 Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel Selected CGRP antagonists, processes for their preparation and their use as medicaments
11/03/2005CA2563635A1 Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine a2a receptor antagonists
11/03/2005CA2559917A1 Compounds as ccri antagonists
11/02/2005EP1590442A2 Macrocyclic hepatitis c serine protease inhibitors
11/02/2005EP1590351A1 Methods for producing quinazoline alkaloids
11/02/2005EP1590350A1 Triazolopyrimidines, methods for the production thereof, use thereof for controlling harmful fungi, and substances containing said triazolopyrimidines
11/02/2005EP1590343A1 Synthesis of 2-butyl-3-(2 -(1-trityl-1h-tetrazol-5-yl)biphen yl-4-yl)-1,3-diazaspirol 4,4 -non-ene-4-one
11/02/2005EP1590340A1 Inhibitors of histone deacetylase
11/02/2005EP1590335A2 Process for preparing pyrrolotriazine kinase inhibitors
11/02/2005EP1501833B1 N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
11/02/2005EP1472256B1 Piperidine derivatives
11/02/2005EP1248824B1 Novel colorants, colorant stabilizers, ink compositions, and improved methods of making the same
11/02/2005EP1246826B1 Chlorophyll and bacteriochlorophyll esters, their preparation and pharmaceutical compositions comprising them
11/02/2005EP0973739B1 N-arylsulfonamide- and pyrrolidinecarboxylic acid intermediates, and their use for the preparation of herbicidal 1,3-dioxo-1h-pyrrolo[1,2-c]imidazole derivatives
11/02/2005EP0907642B1 Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
11/02/2005CN1692116A Adenosine A2A receptor antagonists
11/02/2005CN1692115A Pyrrolopyrimidine and pyrrolopyridine derivatives substituted with cyclic amino group
11/02/2005CN1692114A Novel process for the preparation of pyrazolopyrimidinones
11/02/2005CN1691943A Cancer treatment with go6976 and its related compounds
11/01/2005US6960661 [7-(3-chloro-4-methoxybenzlamino)-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-ylmethoxy]acetic acid, synthesis thereof and intermediates used therein
11/01/2005US6960595 5-6 to 5-7 Heterobicycles as factor Xa inhibitors
11/01/2005US6960593 6,7-dihydro-5H-pyrazolo[1,2a]pyrazol-1-ones which control inflammatory cytokines
11/01/2005US6960592 erectile dysfunction; halosulfonation of 2-ethoxy benzoic acid, sulfonamidation, haloacylation, deacylation and amidation, cyclization; phosphodiesterase inhibitor; side-effect reduction; long lasting
11/01/2005US6960591 Propane-1,3-dione derivative
11/01/2005US6960587 Piperido(1,2-a)piperazine-1,4-dione derivatives fused to a 5-7 membered ring at the 7-8 position; cGMP-specific PDE inhibitors; treatment of cardiovascular disorders and erectile dysfunction.
11/01/2005US6960585 For therapy of inflammatory and immune diseases
11/01/2005US6960584 Inhibitors of Akt activity
11/01/2005US6960583 Pyrazolotriazines as CRF antagonists
11/01/2005US6960582 Such as (3S)-N-(2-(2-(2,4-dichlorophenyl)ethyl)-1-oxo-2,3-dihydro-1H-isoindol-5-yl) -3-methyl-N'-((1S,2S,3S,5R)-2,6,6-trimethylbicyclo(3.1.1)hept-3 -yl)piperazine-1-carboximidamide for treatment of obesity or type II diabetes
11/01/2005US6960474 Method for the treatment of a condition remediable by administration of a selective androgen receptor modulator
10/2005
10/27/2005WO2005100364A1 Processes for the preparation of clopidogrel hydrogen sulfate polymorphic form i
10/27/2005WO2005100356A1 Inhibitors of akt activity
10/27/2005WO2005100355A1 Cyclic amine compound
10/27/2005WO2005100352A1 Selected cgrp-antagonists, their preparation processes and their use as medicaments
10/27/2005WO2005100343A1 Selected cgrp antagonists, method for producing the same and the use thereof as drugs
10/27/2005WO2005100334A1 Dipeptidyl peptidase-iv inhibitors
10/27/2005WO2005099712A2 Process for preparation of n-[3-(3-cyanopyrazolo [1,5-a]pyrimidin-7-yl)phenyl]-n-ethylacetamide
10/27/2005WO2005099688A2 Cyclic compounds
10/27/2005WO2005085250A8 C8, c8' linked 5-oxo-1,2,3,11a-tetrahydro-5h-pyrrolo[2,1-c][1,4]benzodiazepine dimers with 1h-pyrrole-dicarboxylic acid amide linkers and oligomeric analogs therof as well as related compounds for the treatment of proliferative diseases
10/27/2005WO2005070932A3 Substituted heterocyclic compounds and methods of use
10/27/2005WO2005030144A3 Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
10/27/2005WO2005021515B1 Inhibitors of phosphodiesterase type-iv
10/27/2005WO2004058704A8 Quinazolinones as potassium channel modulators
10/27/2005US20050240026 3-step synthesis of pyrazolotriazole couplers and coupler intermediates
10/27/2005US20050239858 Pyrazole derivatives as gnrh inhibitors
10/27/2005US20050239807 allopurinol, oxypurinol, or pterin-6-aldehyde derivatives containing one or more nitrate groups, used for heart failure and stable angina
10/27/2005US20050239806 Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
10/27/2005US20050239795 Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists
10/27/2005US20050239794 Such as aurora-2 kinase or c-kit kinase; anticancer agents; based on benzo(4,5)furo(3,2-d)pyrimidine, 9-thia-1,5,7-triazafluorene, or pyrimido(5,4-b)indole rings; e.g. 4-(4-pyrimid-2-ylaminosulfonyl-1,4-phenylene-aminothiocarbonyl)-piperazin-1-yl)-5H-Pyrimido(5,4-b)indole
10/27/2005US20050239793 Such as aurora-2 kinase or c-kit kinase; anticancer agents; based on benzo(4,5)furo(3,2-d)pyrimidine, 9-thia-1,5,7-triazafluorene, or pyrimido(5,4-b)indole rings; e.g. 6,7-dimethoxy-4-(4-(benzodioxol-5-ylmethylaminothiocarbonyl)-piperazin-1-yl)-5H-Pyrimido(5,4-b)indole
10/27/2005US20050239791 Substituted 1-heteroaryl-4-substituted piperazine and piperidine analogues
10/27/2005US20050239789 2-(9-bromo-3,4,10,10a-tetrahydro-1H-pyrazino[1,2-a]indol-2-yl)-cyclobutanone; treating disorders of the central nervous system, damage to the central nervous system, cardiovascular disorders, gastrointestinal disorders, diabetes insipidus, obesity and sleep apnea
10/27/2005US20050239788 Substituted with pyrrolopiperazine; schizophrenia, psychosis, depression; inhibition of the 5-HT6 receptor
10/27/2005US20050239786 Triazole derivatives as tachykinin receptor antagonists
10/27/2005US20050239784 3-Phenyl analogs of toxoflavine as kinase inhibitors
10/27/2005US20050239773 1-[9-(3-Phenyl-allyl)-3,9 diaza-bicyclo[4.2.1]non-3-yl]-propan-1-one; analgesic; great selectivity to mu receptor; analgesic; pain relief, drug dependence, alcoholism; side effect reduction
10/27/2005US20050239768 Trans-(4a,9b)-2-methyl-2,3,4,4a,5,9b-hexahydro-1H-pyrido[4,3-b]indol-6-yl-4-methylphenyl sulfide; 5-HT2 receptor modulation; schizophrenia, anxiety, depression, and migraines
10/27/2005US20050239767 Intermolecular SNAr of the heterocycle-activated nitro and fluoro groups-application in the synthesis of polyazamacrocyclic ligands
10/27/2005US20050239121 Non-aggregating non-quenching oligomers comprising nucleotide analogs; methods of synthesis and use thereof
10/27/2005US20050236980 Charge transport compositions and electronic devices made with such compounds
10/27/2005DE102004018795A1 Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel Selected CGRP antagonists, processes for their preparation and their use as medicaments
10/27/2005DE102004017739A1 New 2-amino-imidazo(4,5-d)pyridazin-4-one derivatives are dipeptidyl-peptidase IV inhibitors useful in the treatment of e.g. diabetes mellitus, autoimmune disease, rheumatoid arthritis, and multiple sclerosis
10/27/2005CA2563386A1 Selected cgrp-antagonists, their preparation processes and their use as medicaments
1 ... 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 ... 573